

Irina Kulikovskaya

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8604282/irina-kulikovskaya-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17
papers

2,939
citations

15
h-index

19
g-index

19
ext. papers

4,163
ext. citations

22.4
avg, IF

4.11
L-index

#	Paper	IF	Citations
17	Decade-long leukaemia remissions with persistence of CD4 CAR T cells.. <i>Nature</i> , 2022 ,	50.4	30
16	Autologous CD4 ⁺ T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. <i>Molecular Therapy</i> , 2021 , 29, 626-635	11.7	0
15	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	6
14	CRISPR-engineered T cells in patients with refractory cancer. <i>Science</i> , 2020 , 367,	33.3	448
13	Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. <i>Nature Medicine</i> , 2018 , 24, 563-571	50.5	649
12	Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. <i>Molecular Therapy</i> , 2018 , 26, 269-279	11.7	63
11	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. <i>JCI Insight</i> , 2018 , 3,	9.9	90
10	Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. <i>Nature Medicine</i> , 2018 , 24, 1499-1503	50.5	286
9	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. <i>Nature</i> , 2018 , 558, 307-313	50.4	362
8	Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. <i>Cancer Immunology Research</i> , 2017 , 5, 1152-1161	12.5	181
7	Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. <i>PLoS Pathogens</i> , 2017 , 13, e1006613	7.6	68
6	Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. <i>Blood</i> , 2016 , 128, 5702-5702	2.2	23
5	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. <i>Blood</i> , 2016 , 128, 974-974	2.2	27
4	NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. <i>Nature Medicine</i> , 2015 , 21, 914-921	50.5	543
3	Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL. <i>Blood</i> , 2015 , 126, 3769-3769	2.2	34
2	Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL. <i>Blood</i> , 2015 , 126, 683-683	2.2	15
1	Effect of MyBP-C binding to actin on contractility in heart muscle. <i>Journal of General Physiology</i> , 2003 , 122, 761-74	3.4	101

